Printer Friendly

Severe Plasmodium vivax malaria, Brazilian Amazon.

During 2000-2007, in Latin America, a total of 7,554,993 cases of malaria were recorded; 5,507,167 (72.9%) of these cases were caused by Plasmodium vivax parasites. Of the P. vivax malaria cases, 3,833,477 were reported in Brazil, mainly in the Amazon Region (1). Official data from the Brazilian Ministry of Health identify Manaus as one of the leading cities in terms of number of P. vivax malaria cases in Latin America (2).

Manaus (population 1,738,641 in 2009), the capital of the state of Amazonas in the western Brazilian Amazon, is clearly part of a new frontier in the economic development of the Amazon. In 2009, a total of 19,698 cases of malaria were reported in Manaus (annual parasitary index 11.3/1,000 population; 92.6% caused by P. vivax). Since the mid-1990s, as P. vivax was becoming the predominant malaria species in Brazil (3), severe cases and even deaths attributable to P. vivax infection have been reported anecdotally (3). A concomitant trend of increased hospitalization of P. vivax-infected patients was seen in a Manaus tertiary care center (4).

In 2000, one of the authors noted the increased clinical severity of P. vivax cases seen in this same hospital; the frequency of hospitalization was very similar to that of patients infected with P. falciparum (M.G.C.A., unpub. data). Other reports from the same reference center in Manaus have been published regarding unusual complications of P. vivax infection, such as severe rhabdomyolysis (5) and immune thrombocytopenic purpura (6). At the same time, a cascade of reports from areas where P. vivax malaria is highly endemic confirmed the clinical severity of the infections (7). However, to date, data are lacking on the distribution of severe P. vivax malaria, the relationship of patient age, and the identification of possible risk factors. This study describes the clinical features of P. vivax malaria in a case series of patients who were hospitalized in a tertiary care unit in the Brazilian Amazon and their clinical response to treatment with chloroquine.

The Study

The Tropical Medicine Foundation of Amazonas is a tertiary care center for infectious diseases in Manaus (3[degrees]8'S, 60[degrees]1'W). In 2001 and 2002, a total of 13,056 cases of malaria were diagnosed in this institution (11,251 P. vivax), representing 65.1% of the total cases from Manaus. During the same period, 358 (3.2%) patients with P. vivax malaria were hospitalized. A retrospective analysis was performed of case-patients who fulfilled the malaria severity criteria of the World Health Organization (WHO) (8). These patients had an exclusive diagnosis of P. vivax malaria by thick blood smear (reviewed 2 times by experienced microscopists) and PCR, according to the technique described elsewhere (9).

PCR was performed on whole blood from all patients with P. vivax malaria, confirmed by microscopy and any P. falciparum severity criterion recommended by WHO. Blood specimens were routinely stored by the laboratory of the institution at -70[degrees]C. Full clinical information was available from the patients' charts, and serologic tests for dengue virus, Leptospira spp., and hepatitis A, B, and C viruses were performed on available serum samples stored at -20[degrees]C.

Each patient was monitored for 28 days in outpatient clinics after beginning antimalarial treatment. Patients were routinely discharged only after parasitologic clearance and clinical recovery. Until 2006, chloroquine was still prescribed for patients with severe cases at a dose of 10 mg/kg on the first day and 7.5 mg/kg on the second and third days, followed by primaquine (0.5 mg/kg/day for 7 days), according to the Brazilian Ministry of Health guidelines. In 2006, WHO formally recommended the treatment of severe vivax malaria to be the same as that for severe falciparum malaria, because of the risk for an unrecognized mixed infection (8).

Seventeen patients were included in the analysis, and their clinical and laboratory data are shown in Tables 1 and 2, respectively. All patients received chloroquine (orally or through a nasogastric tube) and primaquine. Acute respiratory distress syndrome (ARDS) (diffuse interstitial and alveolar infiltrate by chest radiograph and partial O2 pressure 40 mm Hg by arterial gas analysis) developed in patient 11 two days after she received chloroquine, and she died 3 days later. This patient had a negative thick blood smear from day 3 of treatment with choloroquine. The other 16 patients were followed up after discharge until day 28. None had clinical symptoms of malaria, and all thick blood smears were negative at days 7, 14, and 28.

The patients in whom complications developed exhibited a remarkably wide age range (28 days-80 years). This age range is similar to that seen in other case series from Latin America, such as in hospitalized children from Venezuela with severe anemia that required blood transfusions (10) and in adults from Rondonia (a state in the western Brazilian Amazon) who had severe anemia, jaundice, acute renal failure, ARDS, and shock (11). P. vivax malaria with ARDS has been reported in travelers who acquired the infection in Manaus (12,13). The finding of severe anemia in 4 of 7 children highlights the relevance of this complication in P. vivax infection (Figure), as shown in a prospective study from Papua, Indonesia (14). Nine patients sought treatment for cholestatic jaundice; for 8, jaundice was the only complication. The mechanisms involved are unknown.

The concomitant diagnosis of hepatitis A virus infection in patient 3 (Table 1) indicates that other infectious diseases should be excluded when characterizing severe P. vivax malaria. Also of note is the presence of thrombocytopenia in 15/17 patients (none had clinical bleeding), which suggests that this hematologic complication may be a surrogate marker of severity.

Conclusions

The wide range of parasitemia found in our patients does not enable us to comment on the value of this variable as a determinant of severity. Sixteen patients recovered without the use of antimicrobial drugs; therefore, it is highly improbable that bacterial sepsis was a factor for severity in our case series. In unstable transmission areas (<0.1 autochthonous case per 1,000 persons per year), malaria in older patients may pose an additional problem because chronic diseases (e.g., arterial hypertension and diabetes) may predispose a patient to clinical decompensation.

In vivo chloroquine resistance was not detected in any of the cases that were followed up, despite recent confirmation of the phenomenon in this same locality (15). Because a reliable molecular marker of chloroquine resistance is lacking and parenteral artemisinin derivatives are recommended for treatment of patients with severe P. vivax malaria, studies that assess clinical severity and chloroquine resistance would be unethical. However, our findings suggest that chloroquine resistance would be a problem for individual patients and that the determinants of this resistance need to be clarified. Clearly, areas with chloroquine-resistant P. vivax also report severe P. vivax malaria, but we believe that these studies are not able to establish any firm causality. The finding of both phenomena in some areas may simply reflect high transmission of this species.

Our retrospective review illustrates the spectrum of severe P. vivax malaria in Manaus, and these results parallel the increasing clinical severity described in malaria endemic areas such as Papua (Indonesia) and India. These severe P. vivax cases contribute to increased public health costs because of increased hospitalization and the need for intensive care and blood transfusions. The major complications in patients who required hospitalization were jaundice and severe anemia, although whether these complications were responsible for deaths is undetermined.

[FIGURE OMITTED]

No clear severity criteria exist for P. vivax malaria. However, WHO criteria formerly defined for P. falciparum malaria seem to be applicable to most of the severe P. vivax malaria cases reported in hospital-based studies in the literature. PCR should be performed to rule out mixed infections and other common infectious diseases so that reports from different parts of the world are comparable. Despite the small number of patients, our data corroborate previous findings of severe disease found in areas where chloroquine-resistant P. vivax is being reported but suggest that establishing direct causality is not straightforward. We urgently need to know which clinical complications in P. vivax malaria are associated with death to validate severity criteria. A valid biomarker for chloroquine resistance would also enable associative studies to determine the association between resistance and severity.

DOI: 10.3201/eid1610.100685

Acknowledgments

We thank Pedro Paulo Vieira for support with the molecular diagnosis and Donald Skillman for critical and linguistic review of the manuscript.

This study was supported by the Graduate Program in Tropical Medicine (Fundacao de Medicina Tropical do Amazonas/Universidade do Estado do Amazonas) and Superintendencia da Zona Franca de Manaus.

References

(1.) Pan American Health Organization. Malaria in the Americas: time series epidemiological data from 2000 to 2007. 2008 [cited 2010Apr 20]. http://www.paho.org/Project.asp?SEL=TP&LNG=ENG&ID=55

(2.) Saraiva MG, Amorim RD, Moura MA, Martinez-Espinosa FE, Barbosa MG. Urban expansion and spatial distribution of malaria in the municipality of Manaus, State of Amazonas. Rev Soc Bras Med Trop. 2009;42:515-22.

(3.) Oliveira-Ferreira J, Lacerda MV, Brasil P, Ladislau JL, Tauil PL, Daniel-Ribeiro CT. Malaria in Brazil: an overview. Malar J. 2010;9:115. DOI: 10.1186/1475-2875-9-115

(4.) Santos-Ciminera PD, Roberts DR, Alecrim MG, Costa MR, Quinnan GV Jr. Malaria diagnosis and hospitalization trends, Brazil. Emerg Infect Dis. 2007;13:1597-600.

(5.) Siqueira AM, Alexandre MA, Mourao MP, Santos VS, NagahashiMarie SK, Alecrim MG, et al. Severe rhabdomyolysis caused by Plasmodium vivax malaria in the Brazilian Amazon. Am J Trop Med Hyg. 2010;83:271-3. DOI: 10.4269/ajtmh.2010.10-0027

(6.) Lacerda MV, Alexandre MA, Santos PD, Arcanjo AR, Alecrim WD, Alecrim MG. Idiopathic thrombocytopenic purpura due to vivax malaria in the Brazilian Amazon. Acta Trop. 2004;90:187-90. DOI: 10.1016/j.actatropica.2003.12.001

(7.) Kochar DK, Saxena V, Singh N, Kochar SK, Kumar SV, Das A. Plasmodium vivax malaria. Emerg Infect Dis. 2005;11:132-4.

(8.) World Health Organization. Guidelines for the treatment of malaria. 2006 [cited 2006 Dec 26]. http:/www.who.int/malaria/docs/ TreatmentGuidelines2006.pdf

(9.) Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, Rosario VE, et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993;61:315-20. DOI: 10.1016/0166-6851(93)90077-B

(10.) Rodriguez-Morales AJ, Sanchez E, Vargas M, Piccolo C, Colina R, Arria M. Anemia and thrombocytopenia in children with Plasmodium vivax malaria. J Trop Pediatr. 2006;52:49-51. DOI: 10.1093/ tropej/fmi069

(11.) Andrade BB, Reis-Filho A, Souza-Neto SM, Clarencio J, Camargo LM, Barral A, et al. Severe Plasmodium vivax malaria exhibits marked inflammatory imbalance. Malar J. 2010;9:13. DOI: 10.1186/1475-2875-9-13

(12.) Lomar AV, Vidal JE, Lomar FP, Barbas CV, Matos GJ, Boulos M. Acute respiratory distress syndrome due to vivax malaria: case report and literature review. Braz J Infect Dis. 2005;9:425-30. DOI: 10.1590/S1413-86702005000500011

(13.) Fernandez-Becerra C, Pinazo MJ, Gonzalez A, Alonso PL, Del Portillo HA, Gascon J. Increased expression levels of the pvcrt-o and pvmdr1 genes in a patient with severe Plasmodium vivax malaria. Malar J. 2009;8:55. DOI: 10.1186/1475-2875-8-55

(14.) Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Resistant-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008;5:e128. DOI: 10.1371/journal.pmed.0050128

(15.) de Santana Filho FS, Arcanjo AR, Chehuan YM, Costa MR, Martinez-Espinosa FE, Vieira JL, et al. Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis. 2007;13:1125-6.

Author affiliations: Fundacao de Medicina Tropical do Amazonas, Manaus, Brazil (M.A. Alexandre, C.O. Ferreira, M.P.G. Mourao, M.V. Lacerda); Universidade do Estado do Amazonas, Manaus (M.A. Alexandre, A.M. Siqueira, B.L. Magalhaes, M.P.G. Mourao, M.V. Lacerda, M.G.C. Alecrim); and Centro Universitario Nilton Lins, Manaus (M.A. Alexandre, A.M. Siqueira, M.P.G. Mourao, M.V. Lacerda, M.G.C. Alecrim)

Address for correspondence: Marcus V. Lacerda, Fundacao de Medicina Tropical do Amazonas, Av Pedro Teixeira, 25, Manaus, Amazonas 69040000, Brazil; email: marcuslacerda.br@gmail.com

Dr Alexandre is a malaria researcher at the Tropical Medicine Foundation of Amazonas and is a PhD candidate at the Uni versity of the Amazonas State. Her research interests include characterization of the epidemiology and clinical aspects of P. vivax infection.
Table 1. Clinical characteristics of 17 hospitalized patients who had
parasitologic and molecular diagnosis of Plasmodium vivax infection,
Manaus, Brazil, 2001-2002 *

Patient                                                    Duration of
no.       Year   Age/sex      WHO severity criterion       disease, d

1         2001    2 y/F      Severe anemia ([dagger])           4
2         2001   9 mo/M      Severe anemia ([dagger])          10
3         2001    3 y/F     Jaundice ([double dagger])          3
4         2001   60 y/F         Acute renal failure             7
                                    ([section])
5         2001   1 mo/M      Severe anemia ([dagger])           3
6         2001   40 y/M     Jaundice ([double dagger])          9
7         2001   80 y/M         Acute renal failure             6
                                    ([section])
8         2002    7 y/M           Hemoglobinuria/               4
                            Jaundice ([double dagger])
9         2002   5 mo/M     Severe anemia  ([dagger])/          3
                                       ARDS
10        2002   28 d/M     Jaundice ([double dagger])          5
11        2002   46 y/F      Severe anemia ([dagger])/          5
                                       ARDS
12        2002   48 y/F     Jaundice ([double dagger])          7
13        2002   58 y/M     Jaundice ([double dagger])         12
14        2002   47 y/F     Jaundice ([double dagger])          8
15        2002   43 y/F    Shock ([paragraph])/jaundice         4
16        2002   34 y/M              Jaundice                  10
17        2002   50 y/M              Jaundice                   7

Patient   Antimicrobial   Erythrocyte    Concurrent
no.         drug use      transfusion    condition     ICU   Death

1              No             Yes            --        No     No
2              No             Yes            --        No     No
3              No             No            HAV        No     No
4              No             No          Arterial     No     No
                                        hypertension
5              No             Yes            --        No     No
6              No             No             --        No     No
7              No             No             --        No     No
8              No             Yes            --        No     No
9              No             Yes            --        No     No
10             No             No             --        No     No
11             No             Yes            --        Yes    Yes
12             No             No             --        No     No
13             No             No          Diabetes     No     No
14             No             No             --        No     No
15             Yes            Yes            --        Yes    No
16             No             No             --        No     No
17             No             No             --        No     No

* WHO, World Health Organization; ICU, intensive care unit; HAV,
hepatitis A virus; ARDS, acute respiratory distress syndrome
(tachypnea, shortness of breath, and signs of hypoxemia).

([dagger]) Hemoglobin <7 g/dL in adults and <5 g/dL in children.

([double dagger]) Total bilirubin >3.0 mg/dL.

([section]) Creatinine >3.0 mg/dL.

([paragraph]) Systolic arterial tension <80 mm Hg despite fluid
therapy.

Table 2. Laboratory characteristics of 17 hospitalized patients who
had parasitologic and molecular diagnosis of Plasmodium vivax
infection, Manaus, Brazil, 2001-2002 *

                                               Total leukocyte
Patient       No. asexual        Hemoglobin,        count,
no.       parasites/[mm.sup.3]      g/dL       cells/[mm.sup.3]

1                7,566               3.6            9,700
2                28,847              4.5            9,100
3                1,100               9.5            5,500
4                21,406             14.6            13,900
5                1,862               3.1            19,000
6                1,206              11.5            6,700
7                2,695              12.4            4,900
8                2,055               3.8            13,700
9                3,844               4.5            6,200
10                680                9.6            13,600
11               5,452               6.5            4,700
12               5,047              11.5            4,900
13               11,954              9.4            8,600
14               9,360              12.0            5,200
15               4,524               8.8            5,800
16               5,160              10.7            6,300
17               24,550             10.3            5,000

                                Serum      Serum bilirubin,
Patient    Thrombocytes,     creatinine,   total/conjugated,
no.       cells/[mm.sup.3]      mg/dL            mg/dL

1              97,000            0.5            1.1/0.4
2              30,000            0.6            1.3/0.5
3             143,000            0.4            6.6/5.6
4              33,000            3.0           2.58/1.16
5              99,000            0.7            1.1/0.8
6              27,000            1.2           13.8/10.6
7              76,000            3.7            1.3/0.5
8             106,000            0.6           4.3/0.73
9             171,000            0.3           1.36/0.21
10            275,000            0.1            6.4/4.8
11            107,000            1.7            2.5/1.6
12             35,000            0.9            6.3/5.1
13             48,000            1.0            5.4/5.2
14             27,000            1.2            9.2/7.1
15             29,000            1.0            5.6/4.8
16             36,000            2.3            7.8/6.5
17             24,000            1.4            7.1/4.6

Patient     Serum       Serum
no.       AST, IU/L   ALT, IU/L

1            50          30
2            40          34
3            760        1,233
4            113         108
5            23          56
6            76          60
7            33          33
8            190         37
9            58          25
10           72          50
11           57          56
12           49          34
13           45          43
14           57          53
15           33          30
16           35          70
17           39          55

* WHO, World Health Organization; AST, aspartate aminotransferase;
ALT, alanine aminotransferase.
COPYRIGHT 2010 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:DISPATCHES
Author:Alexandre, Marcia A.; Ferreira, Cynthia O.; Siqueira, Andre M.; Magalhaes, Belisa L.; Mourao, Maria
Publication:Emerging Infectious Diseases
Article Type:Report
Geographic Code:3BRAZ
Date:Oct 1, 2010
Words:2833
Previous Article:Artesunate misuse and Plasmodium falciparum malaria in traveler returning from Africa.
Next Article:Erythema migrans-like illness among Caribbean islanders.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters